Without risk for humans, it might be the basis of a treatment once morest resistant cancers.
Admittedly, the research once morest the cancer make some progress. Both in terms of screening than treatments. Only, some of them remain incurable.
But immunotherapy is making great strides. In Tours, a university team is working on the study of a non-pathogenic micro-organism for humans, and which might well accelerate the discovery of treatments for these types of cancer.
A useful parasite once morest cancer
In The Conversationtwo of these researchers in Tours, Arthur Battistoni (PhD student) and Françoise Debierre-Grockiego (researcher and teacher), recall the interest of immunotherapy:
Unlike chemotherapy and radiotherapy, which prevent the multiplication of tumor cells, but induce serious side effects (because these treatments also attack non-cancerous cells in the body), immunotherapy stimulates the immune system of the patient to fight more specifically once morest cancer.
This parasite is Neospora canine Its interest, beyond being harmless in humans? Its ability to multiply in cells, and its response from the immune system of its host:
Like viruses used in immunotherapy, N. caninum can destroy the cells it infects. It induces a strong cellular immune response, sought to fight once morest cancer. These two characteristics therefore make it a relevant candidate for antitumor immunotherapy.
First tests on mice
Its ability to destroy the cells it takes possession of is of great interest to researchers. A trial was conducted in mice with thymus cancer at the benign stage because it was necessary to test the effectiveness of the parasite first on a treatable cancer.
Results ? No. caninem managed to destroy diseased cells without its presence in healthy cells being accompanied by damage. And the scientists observed the beneficial effects of the parasite on the tumor environment.
Need for further studies
However, researchers need to work on more resistant cancers. more resistant:
N. caninum was no longer detectable at the end of the experiments. Although the human being is not sensitive to a infection by N. caninum, its elimination by the immune system must be confirmed before considering a therapeutic use.
